Oxford Immunotec Global PLC

Oxford Immunotec Global — Investor Presentation (January 2018)

21 slides from Oxford Immunotec Global's investor presentation, Jan 8, 2018

  1. Slide 1: Oxford Immunotec

    299 S§8 Oxford 606 Immunotec

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements Certain information contained in this presentation constitutes forward-looking statements, including those related to future performance and revenues, financial condition, prospects, growth, strategies, expectations and objectives of management. Forward-looking statements

  3. Slide 3: Global locations and facilities

    ‘Memphis, TN ODL CLIA lab + LOT development + Manufacturing Boston,MA US Headquarters, US commercial operations. Imugen and ODL CLIA lab Immunetics business + Tick-borne disease RED Oxford, UK ‘Shanghai, China Yokohama, Japan * OUS Headquarters * China market + Japan Headquarters: * OUS commercial d

  4. Slide 4: Our Target Markets: Immune-Regulated Conditions

    Our Target Markets: Immune-Regulated Conditions Current Focus | Future Focus | Infectious disease + Particularly those that can becomechronic depending on immune control (e.g. TB, Lyme) * Or those that afflict those with weakened immune systems (e.g. TB, CMV, Babesiosis) Transplantation + Relies on

  5. Slide 5: Global capabilities to develop and commercialize proprietary assays

    Global sales + Direct sales forces in US, Europe, Asia hanel + Representation in >50 countries Leverage our Market Demonstrated ability to run multi-centre clinical studies, publish in peer-reviewed capabilities to SSE ETEE journals, change guidelines and establish reimbursement in multiple countrie

  6. Slide 6: Commercial Products and Late-Stage Pipeline

    Commercial Products and Late-Stage Pipeline Brand Market Indication Validation ‘ Infectious Tuberculosis T-SPOT: uci || Tibaes r 2 : 5 ‘YIMUGEN Infectious | Lyme and other tick- sg Y IMMUNETICS~ disease borne diseases B = o ‘YIMUGEN Infectious Babesia blood £ YY immunerics disease screening — 16) Tr

  7. Slide 7: TB Screening

    TB Screening A major global market opportunity geass ¢ In 2016, TB was the 9* leading cause of death worldwide and the leading cause from a single infectious agent’ + ~50M Latent TB Infection (LTBI) screening tests performed each year? .S >$1BN estimated market opportunity? "aa wr! : ~ wel * WHO. “G

  8. Slide 8: Limitations of the tuberculin skin test

    “This method has been inc! al use for more than 90 years. Unfortunately, its a| ionis problematic due to the frequency of false-positive and false-negative skin reactions.” World Health Organization Main Limitations + Lowsensitivity, especially in immunosuppressed, newborns, and elderly + Poor speci

  9. Slide 9: Market Replacing TST with IGRA Blood Tests

    Market Replacing TST with IGRA Blood Tests + Market adopting blood tests called @ interferon-gamma release assays (IGRAs) T-SPOT. o Measure increased IFN-secretion by T cells previously exposedto M. tuberculosis o Use purified M. tuberculosis-specific antigens, such as ESAT-6 & CFP10 + IGRAs have se

  10. Slide 10: Significant Commercial Adoption

    Significant Commercial Adoption With substantial headroom for further growth 2004-8 | CE mark (EU approval), 1* EU guideline, US FDA approval 12,000,000 Mycia: eOUS' (BUS 2019 | CDC guidelines issued in US Chinese SFDA approval 10,000,000 2011 | CPT code & US Medicare reimbursement established & 201

  11. Slide 11: TB Growth Strategy

    TB Growth Strategy + Significant opportunity for continued growth Estimated Global Market Share Split o IGRAsonly ~20% penetrated into market By IGRA and TST Volumes 100% + Expansion of sales resources oom o Leverage revised CDC/ATS/IDSA guidelines in US o Expand Asia presence 2 o Entry into new mar

  12. Slide 12: Tick-borne diseases in the US

    Mosquito-borne Diseases 10% Other Tick-borne Diseases 21% Lyme Disease 69% Lyme disease and other tick-borne diseases are the principal vector-borne diseases in the US* Source: CDC Adams DA, Thomas KR, JajoskyRA, et al. MMWR. 2017 Aug 14 Lyme Disease Anaplasmosis Babesiosis 12 Adverse Health Consequ

  13. Slide 13: The Spread of Lyme Disease

    The Spread of Lyme Disease Reported cases of Lyme Disease to the CDC, 2001 and 2016 7114% * There were ~5m specimens tested for Lyme disease in 2015" - Large and growing market. Estimated US TAM: $400-$500m + oxford mmunotec TAM Analysis for2015 Oxford Source: CDC 13 Immunotec

  14. Slide 14: Importance of Other Tick-borne Infections

    Importance of Other Tick-borne Infections Lyme disease Anaplasmosis Ehrlichiosis Babesiosis Oa Other common tick-borne diseases are prevalent and are expanding Other tick-borne diseases can masquerade as Lyme disease, since symptoms are similar Co-infections in endemic regions are common It is impor

  15. Slide 15: Imugen proprietary tick-borne disease tests

    " Imugen has proprietary tests whose purpose is More sensitive tests required in early detection dy MEARS SeTEN Tm Caniy LTTE MITE well as Lyme and has coinfection data to educate market Need to test for other tick-borne infections as = Imugen covers the major tick-borne diseases, Y xy How mach fran

  16. Slide 16: Multi-year program to build a market leadership position

    Multi-year program to build a market leadership position Clinical & Data Development Leveraging Data & Brand Building The generation and analysis of co-infection and other testing data will aid and direct our commercial, development, and educational initiatives + Investments in the refinement of exi

  17. Slide 17: Babesia Blood Donor Screening and CMV Assay

    Babesia Blood Donor Screening SY immunetics Cytomegalovirus (CMV) Assay + Babesiosis caused by species of Babesia; Babesia microtiis the primary agent in the US Parasite resides in red blood cells - can be transmitted via blood transfusions + Cases of transfusion-transmitted Babesia have grown rapid

  18. Slide 18: 2018 Pipeline Milestones

    2018 Pipeline Milestones Babesia Blood Donor Screening YYIMUGEN” YY immunetics Cytomegalovirus (CMV) Assay T-SPOT. Develop and internally validate assays Develop and internally validate assays Initiate multi-centre study in kidney transplant (PROTECT) File IND, initiate multi-centre studies Complete

  19. Slide 19: Strong revenue growth

    + Strongrevenue growth o FY17 expected to be $103-$103.5m (+~21% YoY CC) © >20% annual CC revenue growth for 13 straight years CQuarterty Revenues ($0008) rs in Oa! Recurring revenue allows us to focus sales teams primarily — on driving growth sto pila + Multiple current and future growth drivers ©

  20. Slide 20: Key Priorities for 2018

    Key Priorities for 2018 Revenue Growth Gross Margin Expansion OpEx Leverage Reduced Cash Burn Focus on growth initiatives in TB and tick-borne disease Anniversary temporary growth headwinds in the US and Asia Possible contribution from pipeline products Full year favorable impact on TB ofthe signifi

  21. Slide 21: Summary & Key Investment Highlights

    Summary & Key Investment Highlights + Playing in large, growing, underserved markets + Differentiated, industry-leading products + Diversified, recurring revenue streams + Rapid revenue growth + Pathway to profitability through gross margin expansion and expense leverage + Strong balance sheet + Bro

Oxford Immunotec Global — Investor Presentation (January 2018) on 6ix